natgillin/translations-raw huggingface dataset:
The CHMP requested clarifications on treatment continuation and more details specific to the individual indications, in particular breast cancer and ovarian cancer. 
CHMP je zahteval pojasnila o nadaljevanju zdravljenja in več podrobnosti za posamezne indikacije, še posebej glede raka dojk in jajčnikov.
If, however, gemcitabine is given every third or fourth day, it can be administered in nonlethal doses with substantial antitumoural activity against a broad spectrum of mouse tumours. 
Če pa gemcitabin dajemo vsak tretji ali četrti dan, ga lahko dajemo v neletalnih odmerkih z znatno protitumorsko aktivnostjo proti širokemu spektru mišjih tumorjev.
Half-life: This ranged from 42 to 94 minutes depending on age and gender. 
Razpolovni čas: V razponu od 42 in 94 minut, odvisno od starosti in spola.
OVERALL SUMMARY OF THE SCIENTIFIC EVALUATION OF GEMZAR 
SPLOŠNI POVZETEK ZNANSTVENEGA VREDNOTENJA ZDRAVILA GEMZAR
Fatigue, which is not associated with anaemia, usually resolves after the first cycle. 
Utrujenost, ki ni povezana z anemijo, se običajno izboljša po prvem ciklusu.
Peripheral blood counts may continue to deteriorate after gemcitabine administration has been stopped. 
Periferne krvne vrednosti se lahko po prekinitvi dajanja gemcitabina še naprej slabšajo.
In vitro, the cytotoxic effect of gemcitabine is dependent on both concentration and time. 
In vitro je citotoksični učinek gemcitabina odvisen tako od koncentracije kot od časa.
Monitoring for toxicity and dose modification due to toxicity 
Spremljanje toksičnosti in sprememba odmerka glede na toksičnost
Paediatric population (< 18 years) 
Otroci (< 18 let)
• Bronchospasm -usually mild and transient but may require parenteral treatment 
• Bronhospazem - zlasti blag in prehoden, vendar bo morda potrebno peroralno zdravljenje
Subsequent cycles should consist of injections once weekly for 3 consecutive weeks out of every 4 weeks. 
V naslednjih ciklusih dajemo injekcije enkrat tedensko v obdobju 3 zaporednih tednov na vsake 4 tedne.
If such effects develop, consideration should be made to discontinuing gemcitabine therapy. 
Če pride do razvoja teh učinkov, je potrebno razmisliti o prekinitvi terapije z gemcitabinom.
Lilly, S.A., Avenida de la Industria, 30 28108 Alcobendas Madrid Spain 
Lilly, S.A., Avenida de la Industria, 30 28108 Alcobendas Madrid Španija
Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. 
V vsaki skupini pogostnosti so neželene reakcije navedene po padajoči resnosti.
Pre-clinical and clinical studies have shown that gemcitabine has radiosensitising activity. 
Predklinične in kliničnih študije so pokazale, da ima gemcitabin radiosenzitizirajoče delovanje.
Do not drive a car or use machinery until you are sure that Gemzar treatment has not made you feel sleepy. 
Ne vozite avtomobila in ne upravljajte z orodji ali stroji, dokler niste prepričani, da vam zdravljenje z zdravilom Gemzar ni povzročilo občutek zaspanosti.
However, the increase in these adverse reactions is not associated with an increased incidence of infections or haemorrhagic events. 
Vendar povečanje neželenih učinkov ni povezano s zvišano incidenco vnetij in hemoragičnih dogodkov.
How frequently you receive your Gemzar infusion depends on the type of cancer that you are being treated for. 
Kako pogosto boste prejemali infuzijo zdravila Gemzar je odvisno od tipa raka za katerega se zdravite.
Prolongation of the infusion time and increased dosing frequency have been shown to increase toxicity. 
Pokazali so, da podaljšanje časa infudiranja in povečana pogostnost odmerjanja povečata toksičnost.
If no safety box is available, the equipment should be supplemented with a mask and protective glasses. 
Če zaščitne komore ni na voljo, opremo nadomestite z masko in zaščitnimi očali.
• you develop breathing difficulties or feel very weak and are very pale (may be a sign of kidney failure). 
• če se vam pojavijo težave z dihanjem ali se počutite šibki in ste zelo bledi (je lahko znak popuščanja ledvic).
Postmarketing experience (spontaneous reports) frequency not known (can't be estimated from the available data) 
Izkušnje v obdobju trženja zdravila (spontana poročila) katerih pogostnost ni znana (ocena iz danih podatkov ni možna)
However, the combination of gemcitabine and cisplatin had a better toxicity profile than MVAC. 
Vendar je imela kombinacija gemcitabina in cisplatina boljši toksikološki profil kot MVAC.
Therefore the CHMP considers that the proposed broad indication “bladder cancer” is not justified, as the data provided was not sufficient to support the indication in superficial bladder cancer. 
Zato je CHMP mnenja, da predlagana, široko zastavljena indikacija "rak sečnega mehurja", ni utemeljena, ker predloženi podatki niso bili zadostni, da bi lahko podprli indikacijo površinskega raka sečnega mehurja.
Gemcitabine does not accumulate when administered once weekly. 
Gemcitabin se pri dajanju enkrat tedensko ne kopiči.
PHADISCO LTD 185 Giannou Kranidioti Avenue CY-2234 Latsia Cyprus 
PHADISCO LTD 185 Giannou Kranidioti Avenue CY-2234 Latsia Ciper
Dose modifications due to haematological toxicity in subsequent cycles, for all indications The gemcitabine dose should be reduced to 75% of the original cycle initiation dose, in the case of the following haematological toxicities: 
Prilagoditve odmerka zaradi hematološke toksičnosti v nadaljnjih ciklusih, za vse indikacije Odmerek gemcitabina je potrebno znižati na 75 % začetnega odmerka prvotnega ciklusa v primeru naslednjih hematoloških toksičnosti:
In patients with impaired bone marrow function, the treatment should be started with caution. 
Pri bolnikih z okvarjenim delovanjem kostnega mozga je potrebno zdravljenje začeti previdno.
FARMASERVE LILLY S.A.Cl 15 Km National Road Athens-Lamia Kifissia, 14564 Greece 
FARMASERVE LILLY S.A.Cl 15 Km National Road Athens-Lamia Kifissia, 14564 Grčija
Percentage of standard dose of Gemzar (%) 
Odstotek standardnega odmerka zdravila Gemzar (%)
Data suggest that gemcitabine can be started after the acute effects of radiation have resolved or at least one week after radiation. 
Podatki kažejo, da lahko z gemcitabinom začnemo po tem, ko akutni učinki obsevanja izzvenijo ali najmanj en teden po obsevanju.
This dosage may be adjusted, or treatment may be delayed depending on your blood cell counts and on your general condition. 
Ta odmerek bo morda prilagojen ali bo zdravljenje preloženo, odvisno od števila vaših krvnih celic in vašega splošnega stanja.
During the week following administration, 92 to 98% of the dose of gemcitabine administered is recovered, 99% in the urine, mainly in the form of dFdU and 1% of the dose is excreted in faeces. 
V tednu po dajanju gemcitabina se izloči 92 do 98 % odmerka gemcitabina, 99 % z urinom, zlasti v obliki dFdU in 1 % z blatom.
At gemcitabine plasma concentrations above 5 µg/ml, dFdCTP levels do not increase, suggesting that the formation is saturable in these cells. 
Pri plazemskih koncentracijah gemcitabina nad 5 µg/ml, se raven dFdCTP ne zviša, kar kaže, da v teh celicah lahko pride do nasičenja.
The dose should be given on Days 1, 8 and 15 of each 28-day cycle in combination with cisplatin. 
Odmerek dajemo 1., 8. in 15. dan vsakega 28-dnevnega ciklusa v kombinaciji s cisplatinom.
You should not be given Gemzar: - if you are allergic (hypersensitive) to gemcitabine or any of the other ingredients of Gemzar. 
Ne uporabljajte zdravila Gemzar: - če ste alergični na (preobčutljivi za) gemcitabin ali katerokoli sestavino zdravila Gemzar.
This improvement in PFS and response rate is only associated with some additional, readily manageable toxicity, resulting in a favourable risk benefit profile. 
To izboljšanje PFS in mere odziva je povezano z zelo majhno mero dodatne, obvladljive toksičnosti, kar ima za posledico ugoden profil tveganj in koristi.
After incorporation into DNA, gemcitabine appears to induce the programmed cell death process known as apoptosis. 
Po vključitvi v DNK, gemcitabin sproži programiran proces celične smrti, znan kot apoptoza.
For Section 4.8, the CHMP requested the clarification of the presentation of the post-marketing spontaneous report and also proposed a list of revised terms to be used in all the tables of adverse event in combination use in this section. 
CHMP je za poglavje 4.8 zahteval pojasnilo predstavitve spontanih poročil, dobljenih po izdaji na trg, in predlagal seznam popravljenih izrazov, ki naj se jih uporabi v tem poglavju v vseh tabelah neželenih učinkov za kombinacijsko uporabo.
Therefore the CHMP agreed with the proposal but asked the MAH to justify the proposed wording regarding 5-FU refractory patients. 
Zaradi tega se je CHMP strinjal s predlogom, vendar je zaprosil imetnika dovoljenja za promet z zdravilom, naj utemelji predlagano besedilo glede neodzivnih bolnikov 5-FU.
Number (%) of Patients MVAC (methotrexate, vinblastine, doxorubicin and cisplatin) arm (N=196) 
Število (%) bolnikov Veja z MVAC (metotreksat, vinblastin, doksorubicin in cisplatin) (N=196)
Laboratory evaluation of renal and hepatic function (including virological tests) should be performed periodically. 
Potrebna je redna laboratorijska ocena ledvičnega in jetrnega delovanja (vključno z virološkimi testi).
It is primarily active against cells in the S phase and is given in the management of solid tumours. 
Zdravilo v prvi vrsti deluje proti celicam v fazi S in se ga daje pri zdravljenju trdnih tumorjev.
The primary metabolite, 2'-deoxy-2', 2'-difluorouridine (dFdU), is not active and is found in plasma and urine. 
Primarni presnovek 2'-dezoksi-2', 2'-difluoruridin (dFdU) ni aktiven in ga najdemo v plazmi in urinu.
There is no known antidote for overdose of gemcitabine. 
Ni znanega antidota za preveliko odmerjanje gemcitabina.
After this addition there is essentially a complete inhibition in further DNA synthesis (masked chain termination). 
Po tem dodatku je pravzaprav popolnoma zavrta nadaljnja sinteza DNK (maskiran konec verige).
If you would like to father a child during the treatment or in the 6 months following treatment, seek advice from your doctor or pharmacist. 
Če bi med zdravljenjem ali v 6 mesecih po zdravljenju želeli spočeti otroka, se posvetujte s svojim zdravnikom ali s farmacevtom.
Gemzar belongs to a group of medicines called “cytotoxics”. 
Zdravilo Gemzar spada v skupino zdravil, imenovanih “citotoksična zdravila”.
Your height and weight are measured to work out the surface area of your body. 
Izmerili vam bodo vašo višino in telesno maso za določitev površino vašega telesa.
Non-concurrent (given >7 days apart)- Analysis of the data does not indicate any enhanced toxicity when gemcitabine is administered more than 7 days before or after radiation, other than radiation recall. 
Ne-sočasno (dana > 7 dni narazen) - Analiza podatkov ne kaže kakršnekoli okrepljene toksičnosti pri dajanju gemcitabina več kot 7 dni pred ali po obsevanju, razen povratne radiacije.
Irregular heart rate (arrhythmia) (frequency not known). 
Nepravilen utrip srca (aritmija) (pogostnost ni znana).
Abnormal urine tests: protein in urine Flu like symptoms including fever Oedema (swelling of ankles, fingers, feet, face) 
Nenormalni urinski testi: beljakovine v urinu Gripi podobni simptomi, vključno z vročino Edem (otečeni gležnji, prsti, noge, obraz)
Pharmacotherapeutic group: pyrimidine analogues ATC code: L01BC05 
Farmakoterapevtska skupina: analogi pirimidinskih baz, oznaka ATC: L01BC05
Handling of the solution for infusion should be done in a safety box and protective coats and gloves should be used. 
Z raztopino za infundiranje morate ravnati v zaščitni komori ter uporabljati zaščitne plašče in rokavice.
These intracellular metabolites have not been detected in plasma or urine. 
Teh znotrajceličnih presnovkov v plazmi ali urinu niso zaznali.
Mild to moderate renal insufficiency (GFR from 30 ml/min to 80 ml/min) has no consistent, significant effect on gemcitabine pharmacokinetics. 
Blaga do zmerna okvara ledvic (GFR od 30 ml/min do 80 ml/min) ni imela skladnega, značilnega učinka na farmakokinetiko gemcitabina.
You must contact your doctor immediately if you notice any of the following: Fever or infection (common): if you have a temperature of 38ºC or greater, sweating or other signs of infection (since you might have less white blood cells than normal which is very common). 
Takoj se obrnite na svojega zdravnika, če opazite karkoli od naštetega: Vročina ali vnetje (pogosto): če imate temperaturo 38 ºC ali več, znojenje ali druge znake vnetja (ker imate morda manj belih krvnih celic kot bi morali, kar je zelo pogosto).
Its action is phase-specific such that gemcitabine primarily kills cells that are undergoing DNA synthesis (S-phase) and, under certain circumstances, blocks the progression of cells at the junction of the G1/S phase boundary. 
Njegovo delovanje je fazno-specifično, tako da gemcitabin primarno ubija celice, ki so v fazi sinteze DNK (S-fazi) in, pod določenimi pogoji blokira razvoj celic v stiku med mejo G1/S faze.
The indication in pancreatic cancer is based on data from the pivotal Phase 3 study JHAY and the supporting study JHAZ. 
Indikacija rak trebušne slinavke temelji na podatkih iz ključne študije III. faze JHAY in podporne študije JHAZ.
Severe skin reactions, including desquamation and bullous skin eruptions, Lyell's Syndrome, StevenJohnson Syndrome 
Hude kožne reakcije, vključno z luščenjem in buloznimi kožnimi vzbrstmi, Lyellov sindrom, StevenJohnsonov sindrom
Solutions of reconstituted gemcitabine should not be refrigerated, as crystallisation may occur. 
Raztopine rekonstituiranega gemcitabina ne smemo shranjevati v hladilniku, ker lahko pride do kristalizacije.
In both studies it was found that tolerability was similar in the two treatment arms. 
V obeh vejah obeh študij so ugotovili, da je bilo prenašanje podobno.
WHAT GEMZAR IS AND WHAT IT IS USED FOR 
KAJ JE ZDRAVILO GEMZAR IN ZAKAJ GA UPORABLJAMO
In the event of suspected overdose, the patient should be monitored with appropriate blood counts and receive supportive therapy, as necessary. 
V primeru suma na preveliko odmerjanje je potrebno spremljati bolnikovo krvno sliko in po potrebi dati ustrezno podporno terapijo.
Gemcitabine solutions are for single use only. 
Raztopine gemcitabina so samo za enkratno uporabo.
No effect on the fertility of females has been detected. 
Učinka na plodnost samic niso zaznali.
A hospital pharmacist or doctor will have dissolved the Gemzar powder before it is given to you. 
Bolnišnični farmacevt ali zdravnik bo pred dajanjem prašek zdravila Gemzar raztopil.
Omit dose* *Treatment omitted will not be re-instated within a cycle. 
Izpuščen odmerek* *Zdravljenje med ciklusom ne bo ponovno uvedeno.
Fever accompanied by low white blood cell count (febrile neutropaenia) Anorexia (poor appetite) 
Vročina spremljana z nizkim številom belih krvnih celic (febrilna nevtropenija) Anoreksija (slab apetit)
Gemzar may be given alone or in combination with other anti-cancer medicines, depending on the type of cancer. 
Zdravilo Gemzar se lahko daje samostojno ali se v kombinaciji z drugimi zdravili proti raku, odvisno od tipa raka.
There is no evidence to suggest that dose adjustments, other than those already recommended for all patients, are necessary in the elderly (see section 5.2). 
Ni dokazov, ki bi kazali, da so pri starejših potrebne dodatne prilagoditve odmerkov, poleg tistih, ki so priporočene za vse bolnike (glejte poglavje 5.2).
• Leucopaenia (Neutropaenia Grade 3 = 19.3 %; Grade 4 = 6 %). 
• Levkopenija (nevtropenija 3. stopnje = 19,3 %; 4. stopnje
LILLY France SAS 13, rue Pagès 92158 Suresnes Cedex France 
LILLY France SAS 13, rue Pagès 92158 Suresnes Cedex Francija
Hydrochloric acid (E507) (for pH adjustment) Sodium hydroxide (E524) (for pH adjustment) 
Klorovodikova kislina (E507) (za uravnavanje pH) Natrijev hidroksid (E524) (za uravnavanje pH)
Oedema is usually reversible after stopping treatment 
Edem je običano revezibilen po prekinitvi zdravljenja.
Concurrent (given together or ≤ 7 days apart) - Toxicity associated with this multimodality therapy is dependent on many different factors, including dose of gemcitabine, frequency of gemcitabine administration, dose of radiation, radiotherapy planning technique, the target tissue, and target volume. 
Sočasna (dana skupaj ali ≤ 7 dni narazen) - Toksičnost, povezana s to večmodalno terapijo, je odvisna od številnih različnih dejavnikov, vključno z odmerkom gemcitabina, pogostnostjo dajanja gemcitabina, odmerkom obsevanja, načrtovano metodo radioterapije, ciljnega tkiva in ciljne prostornine.
Doses should be withheld until toxicity has resolved in the opinion of the physician. 
Odmerjanje je potrebno prekiniti, dokler se toksičnost po mnenju zdravnika ne izboljša.
Yellow fever vaccine and other live attenuated vaccines are not recommended in patients treated with gemcitabine (see section 4.5). 
Uporaba cepiva za rumeno mrzlico in druga živa oslabljena cepiva niso priporočena pri bolnikih, zdravljenih z gemcitabinom (glejte poglavje 4.5).
Gemcitabine plus cisplatin arm (N=200) 
Veja z gemcitabinom in cisplatinom (N=200)
If any of the side effects gets serious, or if you notice any side effects not mentioned in this leaflet, please tell your doctor. 
Če katerikoli neželeni učinek postane resen ali če opazite katerikoli neželeni učinek, ki ni omenjen v tem navodilu, obvestite svojega zdravnika.
In repeat-dose studies of up to 6 months in duration in mice and dogs, the principal finding was schedule and dose-dependent haematopoietic suppression which was reversible. 
V študijah s ponavljajočimi odmerki v trajanju do 6 mesecev na miših in psih je bil najpomembnejši učinek zavrta hematopoeza, odvisna od sheme in odmerka, ki je bila povratna.
For intravenous use after reconstitution 
Za intravensko uporabo po rekonstituciji
Fatigue and febrile neutropaenia occur more frequently when gemcitabine is used in combination with paclitaxel. 
Utrujenost in febrilna nevtropenija se pojavljata bolj pogosto, kadar se gemcitabin uporablja v kombinaciji s paklitakselom.
The CHMP considered the data submitted in support of the bladder cancer indication and noted that all the submitted studies were conducted in patients with locally advanced or metastatic bladder cancer. 
CHMP je pretehtal predložene podatke v podporo indikaciji raka sečnega mehurja in ugotovil, da so bile vse predložene študije izvedene z bolniki, ki so imeli lokalno napredovalega ali metastatskega raka sečnega mehurja.
For storage conditions of the reconstituted medicinal product see section 6.3 
Za pogoje shranjevanja rekonstituiranega zdravila glejte poglavje 6.3.
Antitumoral activity in preclinical models 
Protitumorska aktivnost v predkliničnih modelih
This should be repeated once weekly for up to 7 weeks followed by a week of rest. 
To ponavljamo enkrat tedensko v obdobju do 7 tednov, ki mu sledi tedenska prekinitev.
Gemzar was included in the list of products for SPC harmonisation, in accordance with Article 30(2) of Directive 2001/83/EC, as amended because of the divergences existing amongst the nationally authorised SPCs due to the divergent national decisions taken by Member States. 
Zdravilo Gemzar je bilo vključeno na seznam zdravil, pri katerih je potrebno uskladiti povzetke glavnih značilnosti zdravila v skladu s členom 30(2) Direktive 2001/83/ES, kakor je bila spremenjena, ker so se na državnih ravneh odobreni povzetki glavnih značilnosti zdravila razhajali zaradi razlik v odločitvah držav članic.
This medicine is for single use only; any unused solution should be discarded under the local requirements. 
Zdravilo je samo za enkratno uporabo; neuporabljena raztopina mora biti zavržena v skladu z lokalnimi predpisi.
Low haemoglobin level (anaemia) Low white blood cells 
Nizka raven hemoglobina (anemija) Nizko število belih krvnih celic
Injury, poisoning and procedural complications Radiation recall 
Poškodbe in zastrupitve in zapleti pri posegih Povratna radiacija
Cisplatin has been used at doses between 75-100 mg/m2 once every 3 weeks. 
Cisplatin so uporabljali v odmerkih med 75-100 mg/m površine telesa enkrat na vsake 3 tedne.
Difficulty breathing (it is very common to have mild breathing difficulty soon after the Gemzar infusion which soon passes, however uncommonly or rarely there can be more severe lung problems) 
Težave z dihanjem (zelo pogosto imate lahko kmalu po infuziji zdravila Gemzar blage težave z dihanjem, kar hitro mine, vendar so občasne ali redke lahko tudi bolj hude težave s pljuči).
The CHMP therefore considered that the greatest benefit from gemcitabine is achieved when it is administered in the first and second line setting in combination with taxanes and adopted the following wording: 
CHMP je zaradi tega menil, da je gemcitabin najbolj koristen, če se ga v zdravljenju prve in druge izbire daje v kombinaciji s taksani, zato je sprejel naslednje besedilo:
Evaluation of experimental animal studies has shown reproductive toxicity e.g. birth defects and other effects on the development of the embryo or foetus, the course of gestation or peri- and postnatal development. 
Ocene eksperimentalnih študij na živalih so pokazale vpliv na sposobnost razmnoževanja npr. okvare pri plodu in druge učinke na razvoj zarodka ali ploda, potek brejosti, ali razvoj pred in po porodu.
However, gemcitabine has been reported to cause mild to moderate somnolence, especially in combination with alcohol consumption. 
Vendar so za gemcitabin poročali, da lahko povzroči blago do zmerno zaspanost, zlasti v kombinaciji z uživanjem alkohola.
The volume of distribution of the peripheral compartment was 47.4 l/m2. 
Volumen porazdelitve perifernega dela je bila 47,4 l/m površine telesa.
Common • Increased bilirubin 
Pogosto • Zvišan bilirubin
The frequency of grade 3 and 4 haematological toxicities, particularly neutropaenia, increases when gemcitabine is used in combination with paclitaxel. 
Pogostnost 3. in 4. stopnje hematološke toksičnosti, zlasti nevtropenije je povečana, kadar se gemcitabin uporablja v kombinaciji s paklitakselom.
If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at room temperature, unless reconstitution/dilution has taken place in controlled and validated aseptic conditions. 
Če ga ne uporabimo takoj, sta čas shranjevanja med uporabo in pogoji pred uporabo odgovornost uporabnika in naj običajno ne presegata 24 ur pri sobni temperaturi, razen če je bila rekonstitucija/razredčitev izvedena v nadzorovanih in validiranih aseptičnih pogojih.
Allergic reactions: if you develop skin rash (very common) / itching (common), or fever (very common). 
Alergijske reakcije: če se vam razvije kožni izpuščaj (zelo pogosto) / srbenje (pogosto) ali vročina (zelo pogosto).
• Febrile neutropaenia 
• febrilna nevtropenija
• Alopecia 
• Alopecija
For the recommended gemcitabine dose of 1000 mg/m2 given as a 30-minute infusion, lower clearance values for women and men should not necessitate a decrease in the gemcitabine dose. 
Pri priporočenem odmerku gemcitabina 1.000 mg/m površine telesa, danega kot 30-minutna infuzija, zmanjšan očistek gemcitabina pri ženskah in moških ne zahteva znižanja odmerka gemcitabina.
Gemcitabine monotherapy can be considered in elderly patients or those with performance status 2.” 
Monoterapija z gemcitabinom se lahko uporabi pri starostnih bolnikih ali tistih s statusom učinkovitosti 2.“
Women should be advised not to become pregnant during treatment with gemcitabine and to warn their attending physician immediately, should this occur after all. 
Ženskam je potrebno svetovati naj med zdravljenjem z gemcitabinom ne zanosijo in jih opozoriti naj v primeru, če do tega vseeno pride, takoj obiščejo svojega lečečega zdravnika.
The following pharmacokinetic parameters were obtained for doses ranging from 500 to 2,592 mg/m2 that were infused from 0.4 to 1.2 hours. 
Naslednje farmakokinetične parametre so pridobili iz odmerkov v razponu med 500 in 2.592 mg/m površine telesa, ki so bili infundirani med 0,4 in 1,2 ure.
Cytotoxic activity in cell cultures 
Citotoksična aktivnost v celičnih kulturah
Concomitant radiotherapy 
Sočasna radioterapija